Cited 11 times in

Risk and Risk Score Performance of Hepatocellular Carcinoma Development in Patients With Hepatitis B Surface Antigen Seroclearance

DC Field Value Language
dc.contributor.author김도영-
dc.contributor.author박준용-
dc.contributor.author안상훈-
dc.date.accessioned2021-04-29T17:00:46Z-
dc.date.available2021-04-29T17:00:46Z-
dc.date.issued2021-01-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/182137-
dc.description.abstractIntroduction: Hepatocellular carcinoma (HCC) can develop among chronic hepatitis B patients after hepatitis B surface antigen (HBsAg) seroclearance. However, whether HCC risk after HBsAg seroclearance differs between antiviral therapy (AVT)-induced or spontaneous seroclearance cases and ways to identify at-risk populations remain unclear. Methods: A retrospective cohort of 1,200 adult chronic hepatitis B patients who achieved HBsAg seroclearance (median age: 56 years; 824 men; 165 with cirrhosis; 216 AVT-induced cases) were analyzed. The risk of HCC after HBsAg seroclearance and the performance of 6 HCC prediction models were assessed. Results: During a median of 4.8 years of follow-up (range: 0.5-17.8 years), HCC developed in 23 patients (1.9%). The HCC incidence rate was higher in the AVT-induced cases than that in the spontaneous cases (3.9% vs 0.9% at 5 years). AVT and cirrhosis were independent factors associated with HCC, with HCC incidence rates of 0.5%, 1.2%, 4.0%, and 10.5% at 5 years for spontaneous/no-cirrhosis, AVT-induced/no-cirrhosis, spontaneous/cirrhosis, and AVT-induced/cirrhosis patients, respectively. Among the 6 predictive HCC models tested, Chinese University-HCC score (0.82) showed the highest C-statistics, which was followed by guide with age, gender, HBV DNA, core promoter mutations and cirrhosis (0.81). Discussion: AVT-induced HBsAg seroclearance was associated with higher HCC risk, especially for patients with cirrhosis, indicating that they need careful monitoring for HCC risk. The HCC risk models were able to stratify the HCC risk in patients with HBsAg seroclearance.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherWolters Kluwer Health-
dc.relation.isPartOfCLINICAL AND TRANSLATIONAL GASTROENTEROLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleRisk and Risk Score Performance of Hepatocellular Carcinoma Development in Patients With Hepatitis B Surface Antigen Seroclearance-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorYewan Park-
dc.contributor.googleauthorJeong-Hoon Lee-
dc.contributor.googleauthorDong Hyun Sinn-
dc.contributor.googleauthorJun Yong Park-
dc.contributor.googleauthorMinseok Albert Kim-
dc.contributor.googleauthorYoon Jun Kim-
dc.contributor.googleauthorJung-Hwan Yoon-
dc.contributor.googleauthorDo Young Kim-
dc.contributor.googleauthorSang Hoon Ahn-
dc.contributor.googleauthorWonseok Kang-
dc.contributor.googleauthorGeum-Youn Gwak-
dc.contributor.googleauthorYong-Han Paik-
dc.contributor.googleauthorMoon Seok Choi-
dc.contributor.googleauthorJoon Hyeok Lee-
dc.contributor.googleauthorKwang Cheol Koh-
dc.contributor.googleauthorSeung Woon Paik-
dc.identifier.doi10.14309/ctg.0000000000000290-
dc.contributor.localIdA00385-
dc.contributor.localIdA01675-
dc.contributor.localIdA02226-
dc.relation.journalcodeJ03632-
dc.identifier.eissn2155-384X-
dc.identifier.pmid33433118-
dc.contributor.alternativeNameKim, Do Young-
dc.contributor.affiliatedAuthor김도영-
dc.contributor.affiliatedAuthor박준용-
dc.contributor.affiliatedAuthor안상훈-
dc.citation.volume12-
dc.citation.number1-
dc.citation.startPagee00290-
dc.identifier.bibliographicCitationCLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, Vol.12(1) : e00290, 2021-01-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.